At Emerald Health Pharmaceuticals, our team of scientists, along with researchers from collaborating organizations, have published many scientific articles in high-quality, peer-reviewed journals regarding our proprietary therapies.

Multiple Sclerosis

Cannabidiol and Other Cannabinoids in Demyelinating Diseases”. Int J Mol Sci. (2021) Mar 15;22(6):2992. DOI: 10.3390/ijms22062992. Authors: Navarrete C, García-Martín A, Rolland A, DeMesa J, Muñoz E.

Effects of EHP-101 on inflammation and remyelination in murine models of multiple sclerosis”. Neurobiol Dis. (2020) Sep;143:104994. DOI: 10.1016/j.nbd.2020.104994. Authors: Navarrete C, García-Martin A, Garrido-Rodríguez M, Mestre L, Feliú A, Guaza C, Calzado MA, Muñoz E.

Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy” Journal of Neuroinflammation (2018) 15:64 DOI 10.1186/s12974-018-1103-y Authors: Navarrete C, Carrillo-Salinas F, Palomares B, Mecha M, Jiménez-Jiménez C, Mestre L, Feliú A, Bellido ML, Fiebich BL, Appendino G, Calzado MA, Guaza C and Muñoz E.


EHP-101 alleviates angiotensin II-induced fibrosis and inflammation in mice” Biomedicine & Pharmacotherapy 142 (2021) 112007 Authors: García-Martín A, Navarrete C, Garrido-Rodríguez M, Prados M, Caprioglio D, Appendino G, Muñoz E.

Cannabinoids in Metabolic Syndrome and Cardiac Fibrosis”. Curr Hypertens Rep. (2020) Oct 21;22(12):98. DOI: 10.1007/s11906-020-01112-7. Authors: Navarrete C, Garcia-Martin A, DeMesa J, Muñoz E.

Cannabinoid derivatives acting as dual PPARγ/CB2 agonists as therapeutic agents for systemic sclerosis”. Biochemical Pharmacology (2019) 163:321-334 DOI: 10.1016/j.bcp.2019.02.029. Authors: García-Martín A, Garrido-Rodríguez M, Navarrete C, Caprioglio D, Palomares B, DeMesa J, Rolland A, Appendino G, and Muñoz E.

The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders”. Biochemical Pharmacology (2018) Nov;157:122-133. DOI: 10.1016/j.bcp.2018.08.022. Authors: Río CD, Millán E, García V, Appendino G, DeMesa J, Muñoz E.

EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis”. Biochemical Pharmacology (2018) 157:304-313, DOI: 10.1016/j.bcp.2018.07.047. Authors: García-Martín A, Garrido-Rodríguez M, Navarrete C, Del Río C, Bellido ML, Appendino G, Calzado MA and Muñoz E.

The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways”. Scientific Report (2016) 6:21703, DOI. 10.1038/srep21703. Authors: del Río C, Navarrete C, Collado JA, Bellido ML, Gómez-Cañas M, Pazos MR, Fernández-Ruiz J, Pollastro F, Appendino G, Calzado MA, Cantarero I and Muñoz E.

Parkinson’s Disease

Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its. analogs CBGA-Q and CBGA-Q-Salt in Parkinson’s disease using 6-hydroxydopamine-lesioned mice”. Mol Cell Neuroscience (2021) Jan;110:103583. DOI: 10.1016/j.mcn.2020.103583. Authors: Burgaz S, García C, Gómez-Cañas M, Navarrete C, García-Martín A, Rolland A, Del Río C, Casarejos MJ, Muñoz E, Gonzalo-Consuegra C, Muñoz E, Fernández-Ruiz J.

Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor”. Journal of Neuroinflammation (2018) 15:19 DOI 10.1186/s12974-018-1060-5 Authors: García C, Gómez-Cañas M, Burgaz S, Palomares B, Gómez-Gálvez Y, Palomo-Garo C, Campo S, Ferrer-Hernández J, Pavicic C, Navarrete C, Bellido ML, García-Arencibia M, Pazos MR, Muñoz E and Fernández-Ruiz J.

Development of an oral treatment with the PPAR-γ-acting cannabinoid VCE-003.2 against the inflammation-driven neuronal deterioration in experimental Parkinson’s disease”. Molecules (2019) 24(15). pii: E2702, DOI: 10.3390/molecules24152702. Authors: Burgaz S, García C, Gómez-Cañas M, Muñoz E and Fernández-Ruiz J.

Huntington’s Disease

“VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington’s diseaseScientific Report (2016) July 19;6:29789. Authors: Díaz-Alonso J, Paraíso-Luna J, Navarrete C, del Río C, Cantarero I, Palomares B, Aguareles J, Fernández-Ruiz J, Bellido ML, Pollastro F, Appendino G, Calzado MA, Galve-Roperh I, Muñoz E.

Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration” Translational Neurodegeneration (2019) 8:9 DOI:10.1186/s40035-019-0148-x Authors: Aguareles J, Paraíso-Luna J, Palomares B, Bajo-Grañeras R, Navarrete C, Ruiz-Calvo A, García-Rincón D, García-Taboada E, Guzmán M, Muñoz E and Galve-Roperh I.